Lucrative Opportunity for Anti-Diabetic Drugs as Chinese Patient Population Estimated to Hit 162 Million by 2030
The number of diabetics in China is set to soar, according to independent analyst firm Datamonitor Healthcare. Currently the number of patients stands at more than 118 million, but is estimated to increase by 37% and reach 162 million by 2030.
Sabada Dube, analyst at Datamonitor Healthcare said: “China is experiencing a serious transition phase where chronic diseases such as diabetes are becoming more prominent than infectious disease.
More than half of the diabetes cases in China are in found in urban areas of the country, with lifestyle factors, living standards and increasing urbanisation rates causing the growth. Population changes, population aging and a substantial increase in obesity cases are also major demographic drivers of the epidemic.
Despite the considerable number of diabetes cases in China, only a small proportion of affected individuals are aware they have the disease and are therefore more at risk of heart disease or suffering a stroke.
Sabada Dube continued: “Although rates in urban areas are higher, urbanisation may prove positive for diabetes suffers in China, as diagnosis rates in these areas are higher. Improved or earlier diagnosis will enhance the survival of patients.”
Lu Pengfei, analyst at Datamonitor Healthcare, added: “This growing patient population presents a lucrative opportunity for anti-diabetes drugs. Approximately 13% of China’s total medical expenditure is spent on diabetes.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance